Aimfinity Investment I said it deposited $60,000 into trust to cover another month under its extension plan, which runs until Jan. 28, 2025 in monthly increments.
The SPAC issued a promissory note to its sponsor in the same amount.
Aimfinity in October signed a $60 million merger agreement with Docter Inc., a Taiwanese non-invasive blood glucose watch developer.
Aimfinity shareholders will have approximately 51.92% equity interest in the combined company and Docter stockholders will own 48.08%, assuming no SPAC redemptions.
US Tiger Securities is serving as M&A and Capital Markets advisor and Robinson & Cole is legal advisor to Aimfinity. Winston & Strawn is legal advisor to Docter.
Since 2016, Docter, along with its subsidiary, Horn Enterprise, has been developing a non-invasive blood sugar trend monitoring technology, alleviating the necessity for blood sampling. The company operates Docter brand watches and employs Docter Cloud platform technologies to facilitate health monitoring, vascular elasticity tracking, and myocardial infarction prediction.
Aimfinity raised $70 million in an April 2022 IPO. Read more.
